SVA Sernova Biotherapeutics Inc
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.…
Industry Peers
BiotechnologyKey Statistics
About Sernova Biotherapeutics (TSE: SVA)
›
Sernova Biotherapeutics (TSE: SVA) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 0.0900 CAD on 19 November 2026, down 35.7% over 52 weeks. Its 52-week range is 0.0900 CAD to 0.2000 CAD, and it trades at the bottom of that range.
At a market capitalisation of 33.99M CAD, it trades at 9.0 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 73% for SVA.
Sernova Biotherapeutics reports return on equity of 62.8% and an operating margin of 0.0%.
Its debt exceeds its cash by 2.52M CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 17 December 2026.